

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

Calu-3

RRID:CVCL_0609

Type: Cell Line

Proper Citation

RRID:CVCL_0609

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0609

Proper Citation: RRID:CVCL_0609

Description: Cell line Calu-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:3129183](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3940644](#), [PMID:6220172](#), [PMID:7459858](#), [PMID:7515578](#), [PMID:9636188](#), [PMID:10523844](#), [PMID:11064206](#), [PMID:15463957](#), [PMID:17483357](#), [PMID:18083107](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20090954](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24207061](#), [PMID:25485619](#), [PMID:25555374](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:34339474](#), [PMID:35839778](#), [PMID:35879413](#)

Comments: Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Calu-3

Synonyms: CaLu-3, CALU-3, Calu 3, Calu3, CALU3

Cross References: BTO:BTO_0002750, CLO:CLO_0002192, EFO:EFO_0002819, CLDB:cl634, CLDB:cl635, CLDB:cl5176, Abcam:ab275465, AddexBio:C0016001/30, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-55, BCRJ:0264, BioGRID_ORCS_Cell_line:1375, BioSample:SAMN03471552, BioSample:SAMN10988517, cancercellines:CVCL_0609, CancerTools:161906, CCRID:1101HUM-PUMC000032, CCRID:1101HUM-PUMC000329, CCRID:3101HUMTCHu157, CCRID:4201HUM-CCTCC00647, Cell_Model_Passport:SIDM00922, ChEMBL-Cells:ChEMBL3307390, ChEMBL-Targets:ChEMBL614534, CLS:305032, Cosmic:687777, Cosmic:910562, Cosmic:933578, Cosmic:945227, Cosmic:961842, Cosmic:1006532, Cosmic:1028940, Cosmic:1146873, Cosmic:1219068, Cosmic:1239869, Cosmic:1434969, Cosmic:1802295, Cosmic:2125219, Cosmic:2664117, Cosmic:2772161, Cosmic-CLP:687777, DepMap:ACH-000392, EGA:EGAS00001000610, EGA:EGAS00001002554, GDSC:687777, GEO:GSM108803, GEO:GSM108804, GEO:GSM159355, GEO:GSM159356, GEO:GSM159357, GEO:GSM159358, GEO:GSM253347, GEO:GSM353233, GEO:GSM434276, GEO:GSM513948, GEO:GSM514318, GEO:GSM784249, GEO:GSM794262, GEO:GSM817064, GEO:GSM827549, GEO:GSM886915, GEO:GSM887981, GEO:GSM1374433, GEO:GSM1374434, GEO:GSM1669658, IARC_TP53:21264, IGRhCellID:Calu3, IZSLER:BS TCL 103, KCB:KCB 202003YJ, KCLB:30055, LiGeA:CCL_462, LINCS_HMS:50010, LINCS_LDP:LCL-1631, Lonza:342, MetaboLights:MTBLS762, MetaboLights:MTBLS2352, MetaboLights:MTBLS2840, Millipore:SCC438, PharmacDB:Calu3_179_2019, PRIDE:PRD000594, PRIDE:PXD000589, PRIDE:PXD019645, PRIDE:PXD023418, PRIDE:PXD023422, PRIDE:PXD023760, PRIDE:PXD024242, PRIDE:PXD024375, PRIDE:PXD024883, PRIDE:PXD025499, PRIDE:PXD026302, PRIDE:PXD030304, PRIDE:PXD034135, Progenetix:CVCL_0609, PubChem_Cell_line:CVCL_0609, TOKU-E:768, Wikidata:Q52392355

ID: CVCL_0609

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260815T231957+0000

Ratings and Alerts

No rating or validation information has been found for Calu-3.

No alerts have been found for Calu-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1642 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pasquero S, et al. (2026) Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. *iScience*, 29(3), 115038.

Xu Y, et al. (2026) KCTD10 weakens m6A modification of IL-11 in a ubiquitin-dependent manner to repress tumour immune escape in lung adenocarcinoma. *British journal of pharmacology*, 183(16), 4778.

Criscuolo E, et al. (2026) miR-29a and miR-15b Modulate SARS-CoV-2 Beta and Omicron Infection in Human Lung Epithelial Cells. *International journal of molecular sciences*, 27(13).

Te Marvelde MR, et al. (2026) Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies. *NPJ vaccines*, 11(1), 25.

Chen W, et al. (2026) Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation. *Life sciences*, 394, 124357.

Rae B, et al. (2026) Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding. *Journal of visualized experiments : JoVE*(229).

Wang BL, et al. (2026) Multi-Omics reveals SPP1 + malignant and CXCR4+ TAM crosstalk predicts immunotherapy response in lung adenocarcinoma. *Discover oncology*, 17(1).

Huang P, et al. (2026) Plasma - Activated medium engages redox signaling to activate a VDAC1-TRPML1 lysosomal-mitochondrial Ca²⁺ death pathway. *Free radical biology & medicine*, 253, 622.

Kong W, et al. (2026) Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. *Journal of virology*, 100(4), e0027026.

Shi G, et al. (2026) Uridine cytidine kinase 1 promotes phosphatidylcholine biosynthesis, facilitating SARS-CoV-2 infection. *Molecular cell*.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Minnecci M, et al. (2026) Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. *ChemMedChem*, 21(1), e202501000.

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Chen N, et al. (2026) Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4. Journal of virology, 100(5), e0028226.

Wacharapluesadee S, et al. (2026) Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia. Cell, 189(13), 4075.

Arora P, et al. (2025) Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. Vaccines, 13(4).

Ku D, et al. (2025) SLIRP amplifies antiviral signaling via positive feedback regulation and contributes to autoimmune diseases. Cell reports, 44(5), 115588.

Posch W, et al. (2025) Aloe-derived polysaccharides (APS) mitigate SARS-CoV-2 Omicron BQ1.1 infection by preserving epithelial integrity and reducing viral load in human airway epithelial (HAE) cultures. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 192, 118657.